| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 03/10/2011 | US20110059178 Tissue Engineered Meniscus Repair Composition |
| 03/10/2011 | US20110059177 Cardioplegia Solution for Cardiac Surgery |
| 03/10/2011 | US20110059176 Material for preventing tissue adhesion and material for preventing joint contracture |
| 03/10/2011 | US20110059175 Enhancing solubility and dissolution rate of poorly soluble drugs |
| 03/10/2011 | US20110059174 PKCdelta REGULATES NEUROINFLAMMATORY EVENTS |
| 03/10/2011 | US20110059173 encoding a polypeptide comprising a carboxy-terminal amino acid sequence of an alpha Connexin; reduces scar formation |
| 03/10/2011 | US20110059172 Therapeutic compositions |
| 03/10/2011 | US20110059171 Oral galenic formulation including ketorolac and b-complex vitamins, in which vitamin b6 is in an outer layer separated from the rest of the active principles |
| 03/10/2011 | US20110059170 Methods for administering weight loss medications |
| 03/10/2011 | US20110059169 Method and Composition for Administering an NMDA Receptor Antagonist to a Subject |
| 03/10/2011 | US20110059168 Method for correcting intestinal glutamine synthetase deficiency |
| 03/10/2011 | US20110059167 Encapsulation of biologically active agents |
| 03/10/2011 | US20110059166 High strength seamless alginate capsules |
| 03/10/2011 | US20110059165 Seamless alginate capsules |
| 03/10/2011 | US20110059164 Encapsulation of oxidatively unstable compounds |
| 03/10/2011 | US20110059163 Lyophilised antigen composition |
| 03/10/2011 | US20110059162 Tannin-chitosan composites |
| 03/10/2011 | US20110059161 Targeted delivery using tissue-specific peptidomimetic ligands |
| 03/10/2011 | US20110059160 Methods and compositions for targeted gene modification |
| 03/10/2011 | US20110059159 Nanoscale bound bilayers, methods of use and production |
| 03/10/2011 | US20110059158 Charged phospholipid compositions and methods for their use |
| 03/10/2011 | US20110059157 Anionic lipids and lipid nano-structures and methods of producing and using same |
| 03/10/2011 | US20110059156 Nanostructures Suitable for Sequestering Cholesterol and Other Molecules |
| 03/10/2011 | US20110059155 Water resistant patch preparation |
| 03/10/2011 | US20110059153 Use of anti-cytokine agents for treating carpal and tarsal tunnel syndrome |
| 03/10/2011 | US20110059147 Long term drug delivery devices with polyurethane based polymers and their manufacture |
| 03/10/2011 | US20110059142 Encapsulation of biologically active agents |
| 03/10/2011 | US20110059141 Percutaneous absorption preparations of antidementia drugs |
| 03/10/2011 | US20110059140 Extruded rod-shaped devices for controlled release of biological substances to humans and animals |
| 03/10/2011 | US20110059139 Method for loading a molecule into a porous substrate |
| 03/10/2011 | US20110059027 Biocidal aldehyde composition |
| 03/10/2011 | US20110059026 Pharmaceutical dosage form bearing pregnancy-friendly indicia |
| 03/10/2011 | US20110059024 Liposome composition, and diagnostic contrast agent, therapeutic enhancer, and pharmaceutical composition using the same |
| 03/10/2011 | US20110059020 Liposome composition, and diagnostic contrast agent, therapeutic enhancer, and pharmaceutical composition using the same |
| 03/10/2011 | US20110056863 Adhesive preparation containing donepezil, and package of the same |
| 03/10/2011 | US20110056492 Effective delivery of nanoparticles and micrometer-sized pharmaceutical aerosols to the lung through enhanced condensational growth |
| 03/10/2011 | CA2805749A1 Pharmaceutical formulations and methods of use |
| 03/10/2011 | CA2777225A1 Granulated anthelmintic preparations and delivery systems |
| 03/10/2011 | CA2773037A1 Clarithromycin extended-release tablet |
| 03/10/2011 | CA2773033A1 Use of aerosolized levofloxacin for treating cystic fibrosis |
| 03/10/2011 | CA2772878A1 Ganglioside transmucosal formulations |
| 03/10/2011 | CA2772708A1 Oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles |
| 03/10/2011 | CA2772660A1 Delivery of therapeutic agents using oligonucleotide-modified nanoparticles as carriers |
| 03/10/2011 | CA2772622A1 Ketorolac tromethamine compositions for treating or preventing ocular pain |
| 03/10/2011 | CA2772496A1 Extended use medical device |
| 03/10/2011 | CA2772144A1 Scented capsules |
| 03/10/2011 | CA2772057A1 Targeted delivery using tissue-specific peptidomimetic ligands |
| 03/10/2011 | CA2771747A1 Hot-melt extruded compositions containing plant-derived phenolic materials and processes for the preparation thereof |
| 03/10/2011 | CA2738117A1 Composition containing ultra-micronized palmitoyl-ethanolamide |
| 03/09/2011 | EP2292584A1 Levalbuterol L-hemitartrate salt and aerosol formulation thereof |
| 03/09/2011 | EP2292268A1 Pharmaceutical composition for use in treatment of diabetes |
| 03/09/2011 | EP2292263A2 Compositions and methods for stabilizing biological molecules upon lyophilization |
| 03/09/2011 | EP2292253A2 Stabilized pharmaceutical peptide compositions |
| 03/09/2011 | EP2292247A2 Immunizing composition and method for inducing an immune response against the beta-secretase cleavage site of amyloid precursor protein |
| 03/09/2011 | EP2292242A1 A scutellarin derivative, the preparing process, the pharmaceutical composition and the use thereof |
| 03/09/2011 | EP2292241A1 A scutellarin derivative, the preparing process, the pharmaceutical composition and the use thereof |
| 03/09/2011 | EP2292239A2 Remedies for diseases to be applied to eye |
| 03/09/2011 | EP2292235A2 Methotrexate solutions |
| 03/09/2011 | EP2292234A1 Compositions comprising quinazoline derivatives, preparation methods and uses thereof |
| 03/09/2011 | EP2292233A2 Pharmaceutical uses of N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine |
| 03/09/2011 | EP2292230A1 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic |
| 03/09/2011 | EP2292229A1 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic |
| 03/09/2011 | EP2292225A1 Dosage form comprising taxol in crystalline form |
| 03/09/2011 | EP2292219A1 Transdermal therapeutic system for the administration of rivastigmine |
| 03/09/2011 | EP2292218A2 Nimesulide and muscle relaxant combinations thereof |
| 03/09/2011 | EP2292217A2 Modified release lamotrigine tablets |
| 03/09/2011 | EP2292216A2 Stable pharmaceutical composition containing factor VIII |
| 03/09/2011 | EP2292215A2 Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof |
| 03/09/2011 | EP2292214A1 Highly absorbable drug composition and method of producing the same |
| 03/09/2011 | EP2292213A1 Compositions comprising a polymorphic form of armodafinil |
| 03/09/2011 | EP2292212A2 Method of making particles for use in a pharmaceutical composition |
| 03/09/2011 | EP2292211A2 Mucoadhesive pharmaceutical formulations |
| 03/09/2011 | EP2292210A1 Preparation for the prevention and/or treatment of dementia syndromes |
| 03/09/2011 | EP2292209A2 Stable pharmaceutical composition comprising a pyramidine-sulfamide |
| 03/09/2011 | EP2292184A1 Implantable stent prosthesis |
| 03/09/2011 | EP2292097A2 Recombinant parainfluenza virus expression systems and vaccines |
| 03/09/2011 | EP2291460A2 Surface-modified nanoparticles |
| 03/09/2011 | EP2291350A2 Compositions and methods for preparing and using same |
| 03/09/2011 | EP2291325A2 Methods for controlling heat generation of magnetic nanoparticles and heat generating nanomaterials |
| 03/09/2011 | EP2291233A1 Method and apparatus for dry granulation |
| 03/09/2011 | EP2291199A2 Capsulating system binding to nucleolin |
| 03/09/2011 | EP2291198A2 Vesicles comprising an amphiphilic block copolymer for use in epithelial delivery |
| 03/09/2011 | EP2291180A1 Anhydrous depigmenting compositions comprising, within the fatty phase, a solubilized phenolic derivative and a retinoid |
| 03/09/2011 | EP2291178A2 Controlled release formulations of pramipexole |
| 03/09/2011 | EP2291177A2 Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale |
| 03/09/2011 | EP2291176A1 Steroid nebuliser formulation |
| 03/09/2011 | EP2291175A1 Administrable compositions |
| 03/09/2011 | EP2291174A1 Biocompatible oligomer-polymer compositions |
| 03/09/2011 | EP2291163A1 Container for medical products and method for production of said container |
| 03/09/2011 | EP2291081A1 Povidone iodine, a novel alternative preservative for ophthalmic compositions |
| 03/09/2011 | EP2178512B1 Tableted compositions containing atazanavir |
| 03/09/2011 | EP2117510B1 Parenteral pharmaceutical composition and method for preparing the same |
| 03/09/2011 | EP1722759B1 Composition containing chitosan and a polyol-phosphate or a sugar-phosphate |
| 03/09/2011 | EP1708685B1 Effervescent oral opiate dosage forms and methods of administering oxycodone |
| 03/09/2011 | EP1701703B1 Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers and stabilizing polymers |
| 03/09/2011 | EP1575548B1 Compositions and methods for promoting neuronal outgrowth |
| 03/09/2011 | EP1499297B1 Pharmaceutical formulation comprising atorvastatin calcium |
| 03/09/2011 | EP1355910B1 Formulation of boronic acid compounds |
| 03/09/2011 | EP1194113B1 Use of bioactive glass as a preservative for cosmetic and pharmaceutical preparations |
| 03/09/2011 | EP1135178B1 Polymeric coatings with controlled delivery active agents |